{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:28:40Z","timestamp":1786796920031,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.radonc.2026.111650","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:20:56Z","timestamp":1781911256000},"page":"111650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Is there an association between acute, subacute, and late genitourinary quality of life with prostate SBRT boost?"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3310-2091","authenticated-orcid":false,"given":"Li","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4929-0278","authenticated-orcid":false,"given":"Jarad","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pryor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Leigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0795-0984","authenticated-orcid":false,"given":"Eric","family":"Wegener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111650_b0005","unstructured":"Cancer data in Australia, Overview of cancer in Australia, 2024. Australian Institute of Health and Welfare. December 9, 2024. Accessed September 28, 2025. https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia\/contents\/overview."},{"key":"10.1016\/j.radonc.2026.111650_b0010","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"A phase III randomized controlled trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111650_b0015","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.euo.2024.01.008","article-title":"Prostate virtual high-dose-rate brachytherapy boost: 5-year results from the PROMETHEUS prospective multicentre trial","volume":"7","author":"Wegener","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2026.111650_b0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111650_b0025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(24)00720-4","article-title":"The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials","volume":"26","author":"Nikitas","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111650_b0030","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3390\/cancers15041288","article-title":"The association between acute and late genitourinary and gastrointestinal toxicities: an analysis of the PACE B study","volume":"15","author":"Ratnakumaran","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2026.111650_b0035","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline","volume":"33","author":"Di Maio","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111650_b0040","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.juro.2013.09.040","article-title":"Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice","volume":"191","author":"Chipman","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2026.111650_b0045","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.ijrobp.2021.01.034","article-title":"Underascertainment of clinically meaningful symptoms during prostate cancer radiation therapy-does this vary by patient characteristics?","volume":"110","author":"Sud","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111650_b0050","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/s12885-018-4511-6","article-title":"PROstate Multicentre External beam radiotherapy using a Stereotactic boost: the PROMETHEUS study protocol","volume":"18","author":"Richardson","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2026.111650_b0055","unstructured":"ANZCTR - Registration. Accessed February 18, 2026. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=367980."},{"key":"10.1016\/j.radonc.2026.111650_b0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the expanded prostate cancer index composite short form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2026.111650_b0065","first-page":"111","article-title":"Evaluating the measurement properties of the 26-item Expanded Prostate Cancer Index Composite (EPIC-26) with a multicenter cohort","volume":"14","author":"Crump","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.radonc.2026.111650_b0070","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s11136-021-02940-z","article-title":"The expanded prostate cancer index composite short form (EPIC-26) for measuring health-related quality of life: content analysis of patients\u2019 spontaneous comments written in survey margins","volume":"31","author":"Talvitie","year":"2022","journal-title":"Qual Life Res"},{"key":"10.1016\/j.radonc.2026.111650_b0075","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/JU.0000000000000392","article-title":"Interpretation of domain scores on the expanded prostate cancer index composite: how does the domain score translate into functional outcomes?","volume":"202","author":"Laviana","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2026.111650_b0080","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ijrobp.2016.11.008","article-title":"Acute and late adverse events associated with radical radiation therapy prostate cancer treatment: a systematic review of clinician and patient toxicity reporting in randomized controlled trials","volume":"97","author":"Holch","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111650_b0085","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/cancers14071670","article-title":"A comparison between patient- and physician-reported late radiation toxicity in long-term prostate cancer survivors","volume":"14","author":"Nuijens","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2026.111650_b0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eururo.2025.07.007","article-title":"Exploring factors associated with late urinary toxicity after prostate stereotactic body radiotherapy: findings from the PACE-B study","volume":"89","author":"Ratnakumaran","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111650_b0095","first-page":"6373","article-title":"Late toxicity rates following definitive radiotherapy for prostate cancer","volume":"19","author":"Ohri","year":"2012","journal-title":"Can J Urol"},{"key":"10.1016\/j.radonc.2026.111650_b0100","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(22)00544-7","article-title":"Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy","volume":"23","author":"Martin","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111650_b0105","unstructured":"Majeed H, Gupta V. Adverse effects of radiation therapy. In: StatPearls. StatPearls Publishing; 2025. Accessed August 10, 2025. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563259\/."},{"key":"10.1016\/j.radonc.2026.111650_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104948","article-title":"Individual radiosensitivity testing in 2025: current advances and future directions for personalized radiotherapy","volume":"216","author":"Debbi","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2026.111650_b0115","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fonc.2014.00290","article-title":"Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer","volume":"4","author":"Rana","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111650_b0120","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3390\/jcm12072536","article-title":"Physiotherapy as an effective method to support the treatment of male urinary incontinence: a systematic review","volume":"12","author":"Mazur-Bialy","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.radonc.2026.111650_b0125","first-page":"165","article-title":"Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: a scoping review","volume":"42","author":"Neerhut","year":"2024","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.radonc.2026.111650_b0130","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111650_b0135","first-page":"211","article-title":"Long-term urinary continence and influencing factors after salvage radiotherapy: results of the SAKK 09\/10 dose escalation trial","author":"Schr\u00f6der","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111650_b0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijrobp.2009.07.1742","article-title":"Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy","volume":"78","author":"Jereczek-Fossa","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111650_b0145","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.radonc.2004.09.016","article-title":"Urinary incontinence in prostate cancer patients treated with external beam radiotherapy","volume":"74","author":"Liu","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111650_b0150","doi-asserted-by":"crossref","unstructured":"Wang K, Mavroidis P, Royce TJ, et al. Prostate SBRT: an overview of genitourinary\/rectal toxicity and dose response. Int J Radiat Oncol Biol Phys. Published online December 22, 2020:S0360-3016(20)34356-X. doi: 10.1016\/j.ijrobp.2020.09.054.","DOI":"10.1016\/j.ijrobp.2020.09.054"},{"key":"10.1016\/j.radonc.2026.111650_b0155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: a combined analysis of 23 prospective clinical trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16_suppl","key":"10.1016\/j.radonc.2026.111650_b0160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.12039","article-title":"PROSTOX, a signature of late GU toxicity after SBRT radiotherapy in MIRAGE, a prospective trial","volume":"42","author":"Kishan","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:19:15Z","timestamp":1786796355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026004895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"alternative-id":["S0167814026004895"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111650","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there an association between acute, subacute, and late genitourinary quality of life with prostate SBRT boost?","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111650"}}